Biovica Receives Ninth Work Order From a Leading Global Pharmaceutical ...

(PR-inside.com) UPPSALA, SE / ACCESS Newswire / July 14, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a company specializing in blood-based cancer monitoring, today announced that it has received a new work order from a current customer, one of the world's leading pharmaceutical companies with a strong oncology pipeline. This marks the ninth work order received from the same customer, further strengthening the ongoing collaboration. The work order covers DiviTum® TKa testing services for a clinical breast cancer study evaluating a next-generation CDK inhibitor in combination with endocrine therapy. The study includes serial TKa testing over a period of up to four ..

Breakout Wellness UK Empowers the Next Generation of Wellness Innovators

A new accelerator programme from Growth Studio will support ambitious founders building the UK's next generation of health and wellness brands. LONDON, July 14, 2026 /PRNewswire/ -- Growth Studio has today announced the launch of Breakout Wellness UK - a new accelerator programme designed...

People in the UK fear cancer and heart disease – but overlook one of the biggest killers of working-age adults

Tuesday 14 July, 2026 **EMBARGOED UNTIL 00:01 14th July 2026** New data released today has revealed that just 9% of people actively think about or monitor their liver health despite liver disease being one of the leading causes of premature death among working-age adults. Liver disease is largely absent from the UK's biggest health concerns according to a major new survey published today and commissioned by Liver UK, the new charity formed by the merger of the British Liver Trust and Children's Liver Disease Foundation. When asked to name the three health conditions they worry about most, respondents overwhelmingly identified cancer, heart disease, stroke and mental health. Liver disease barely featured, even though it caused more than 12,300 deaths across the UK in 2023 and remains one of

Americans for Ibogaine Welcomes Milestone as Federal Government Mobilizes ...

(PR-inside.com) HHS announcement marks the latest milestone in a movement led by Americans for Ibogaine. HHS, VA, FDA, NIH, ARPA-H and HRSA announce coordinated actions implementing Executive Order, accelerating research, clinical readiness and the pathway toward future FDA-approved psychedelic therapies. WASHINGTON, D.C. / ACCESS Newswire / July 14, 2026 / Americans for Ibogaine (AFI) today welcomed the coordinated, government-wide implementation of the Executive Order advancing psychedelic medicine, including a landmark HHS-VA partnership, new federal actions to accelerate ibogaine research, and efforts to prepare the healthcare system for the responsible deployment of future FDA-approved psychedelic therapies. Just 18 months ago, ibogaine and psychedelic medicine ..

XRP Healthcare, the First AI Healthcare Platform Built on the XRP Ledger, Announces BitMart Listing of XRPHAI

Trading of XRPHAI/USDT begins on BitMart on 14 July 2026 at 10:00 UTC as XRP Healthcare expands its AI healthcare ecosystem with intelligent healthcare agents, Proof of Health™ and blockchain-powered healthcare engagement. DUBAI, UAE, July 14, 2026 /PRNewswire/ -- XRP Healthcare, the...

IGC Pharma (NYSE: IGC) Showcasing 7 AI Breakthroughs Advancing Alzheimer’s Drug Discovery at AAIC 2026

ALZHEIMER'S BLOOD TEST COULD BRING HIGHLY ACCURATE DIAGNOSIS INTO EVERYDAY CLINICAL CARE

A blood test for Alzheimer's disease biomarkers helped improve diagnostic accuracy among specialists and primary care physicians in a real-world study. In a head-to-head comparison after reviewing blood test results, primary care physicians and specialists both had a diagnostic accuracy...

Erasca Announces Pricing of Upsized Public Offering of Common Stock

SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of $17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $550.0 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection...

Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company’s common stock at the amended and reduced exercise price of $6.00. The resale of the shares of common stock issuable upon exercise of the November 2025 Warrants has been registered

Reynolds Road Surgical Center Notice of Data Privacy Incident

TOLEDO, Ohio, July 13, 2026 /PRNewswire/ -- Reynolds Road Surgical Center LLC, doing business as Wildwood Surgical Center ("Wildwood"), writes to notify you of a data security incident involving personal information of certain members of our health care community. What Happened: On June...

ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future

Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapies NEW YORK, July 13, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved a weekly subcutaneous starting...